Immunomedics announces collaborations with cancer research institutions

Immunomedics announces collaborations with cancer research institutions  announced a collaboration with the Yale Cancer Center at the Yale University School of Medicine to evaluate Immunomedics’ lead ADC product candidate, sacituzumab govitecan, as a single agent in two Phase 2 studies in patients with persistent or recurrent endometrial and cervical cancers. In addition to the planned Phase 2 studies, Dr. Santin will also be conducting preclinical evaluation of sacituzumab govitecan as a single agent and in combination with poly polymerase inhibitors in animal in vivo models of gynecologic cancers. Following that principle, the Company has also entered into a research collaboration with the Memorial Sloan Kettering Cancer Center to assess sacituzumab govitecan as a single agent and in combination with epidermal growth factor receptor and phosphoinositide 3-kinase inhibitors, and cisplatin in head and neck cancer in vitro and in vivo models. Furthermore, a separate research collaboration was also established between the Company and Fred Hutchinson Cancer Research Center to investigate sacituzumab govitecan and labetuzumab govitecan, an ADC that targets CEACAM5, as single agent and in combination in prostate cancer xenograft models.

https://bit.ly/2OujThc